JP2020536892A - 医薬レジネート組成物、それを作製する方法、およびその使用 - Google Patents

医薬レジネート組成物、それを作製する方法、およびその使用 Download PDF

Info

Publication number
JP2020536892A
JP2020536892A JP2020520112A JP2020520112A JP2020536892A JP 2020536892 A JP2020536892 A JP 2020536892A JP 2020520112 A JP2020520112 A JP 2020520112A JP 2020520112 A JP2020520112 A JP 2020520112A JP 2020536892 A JP2020536892 A JP 2020536892A
Authority
JP
Japan
Prior art keywords
less
pharmaceutical composition
activator
composition according
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020520112A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536892A5 (cg-RX-API-DMAC10.html
Inventor
サダトレザエイ，モーセン
フルンジ，ジェラルド，ピー．
Original Assignee
ローズ ファーマシューティカルズ エル．ピー．
ローズ ファーマシューティカルズ エル．ピー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ローズ ファーマシューティカルズ エル．ピー．, ローズ ファーマシューティカルズ エル．ピー． filed Critical ローズ ファーマシューティカルズ エル．ピー．
Publication of JP2020536892A publication Critical patent/JP2020536892A/ja
Publication of JP2020536892A5 publication Critical patent/JP2020536892A5/ja
Priority to JP2023090883A priority Critical patent/JP2023123471A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020520112A 2017-10-09 2018-10-08 医薬レジネート組成物、それを作製する方法、およびその使用 Withdrawn JP2020536892A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023090883A JP2023123471A (ja) 2017-10-09 2023-06-01 医薬レジネート組成物、それを作製する方法、およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762569813P 2017-10-09 2017-10-09
US62/569,813 2017-10-09
PCT/US2018/054830 WO2019074829A1 (en) 2017-10-09 2018-10-08 RESINATE-BASED PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEM

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023090883A Division JP2023123471A (ja) 2017-10-09 2023-06-01 医薬レジネート組成物、それを作製する方法、およびその使用

Publications (2)

Publication Number Publication Date
JP2020536892A true JP2020536892A (ja) 2020-12-17
JP2020536892A5 JP2020536892A5 (cg-RX-API-DMAC10.html) 2021-11-18

Family

ID=66100936

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020520112A Withdrawn JP2020536892A (ja) 2017-10-09 2018-10-08 医薬レジネート組成物、それを作製する方法、およびその使用
JP2023090883A Pending JP2023123471A (ja) 2017-10-09 2023-06-01 医薬レジネート組成物、それを作製する方法、およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023090883A Pending JP2023123471A (ja) 2017-10-09 2023-06-01 医薬レジネート組成物、それを作製する方法、およびその使用

Country Status (9)

Country Link
US (3) US11690840B2 (cg-RX-API-DMAC10.html)
EP (1) EP3694555A4 (cg-RX-API-DMAC10.html)
JP (2) JP2020536892A (cg-RX-API-DMAC10.html)
KR (1) KR102901919B1 (cg-RX-API-DMAC10.html)
CN (2) CN111629758A (cg-RX-API-DMAC10.html)
AU (3) AU2018347991A1 (cg-RX-API-DMAC10.html)
CA (1) CA3078844A1 (cg-RX-API-DMAC10.html)
IL (2) IL311303B2 (cg-RX-API-DMAC10.html)
WO (1) WO2019074829A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102881925B1 (ko) * 2022-02-22 2025-11-06 인제대학교 산학협력단 양이온교환수지를 사용한 약물의 방출 조절을 위한 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5369822A (en) * 1976-11-26 1978-06-21 Pennwalt Corp Pharmaceutical agent
JP2009530298A (ja) * 2006-03-16 2009-08-27 トリス・フアルマ・インコーポレーテツド 薬剤−イオン交換樹脂複合体を含有する放出調節製剤
JP2010529040A (ja) * 2007-05-30 2010-08-26 ネオス・セラピューティクス・エルピー イオン性樹脂系の懸濁液における薬物放出の調節
US20140093578A1 (en) * 2010-10-20 2014-04-03 Tris Pharma, Inc. Novel clonidine formulation
JP2016516698A (ja) * 2013-03-13 2016-06-09 トリス・フアルマ・インコーポレーテツド ベンゾナテート改変放出性固体錠剤およびカプセル剤
JP2016222730A (ja) * 2000-02-08 2016-12-28 ユーロ−セルティーク エス．エイ． オピオイドアゴニストおよびアンタゴニストを含む制御放出組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP1204406A2 (en) * 1999-07-29 2002-05-15 Roxane Laboratories, Inc. Opioid sustained-released formulation
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
AR039744A1 (es) * 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
US8343546B2 (en) * 2005-09-13 2013-01-01 Coating Place, Inc. Ion exchange resin treated to control swelling
JP5482012B2 (ja) * 2008-09-19 2014-04-23 セイコーエプソン株式会社 ターゲット支持装置、ターゲット搬送機構及び液体噴射装置
WO2011063164A2 (en) * 2009-11-18 2011-05-26 Steady Sleep Rx Co., Inc. Sustained release cannabinoid medicaments
WO2011107855A2 (en) * 2010-03-04 2011-09-09 Torrent Pharmaceuticals Limited Sustained release oral liquid suspension dosage form
US20130230587A1 (en) 2010-11-10 2013-09-05 Rubicon Research Private Limited Sustained release compositions
RU2013136350A (ru) * 2011-02-02 2015-03-27 АЛФАРМА ФАРМАСЬЮТИКЭЛЗ, ЭлЭлСи Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист
EP2726065A4 (en) 2011-06-30 2014-11-26 Neos Therapeutics Lp MISS-BROKEN MEDICINAL PRODUCTS
WO2013119231A1 (en) 2012-02-09 2013-08-15 Tris Pharma, Inc. Abuse resistant opioid drug - ion exchange resin complexes having hybrid coatings
TW201722406A (zh) 2012-03-02 2017-07-01 羅德製藥公司 抗破壞性立即釋出型調製劑類
MA41152A (fr) 2014-12-12 2017-10-17 Johnson & Johnson Consumer Inc Procédé de fabrication de particules de résinate de phényléphrine ; particules de résinate de phényléphrine et utilisation des particules de résinate de phényléphrine dans des formulations pharmaceutiques
EP3522890A4 (en) * 2016-10-10 2020-06-03 Rhodes Pharmaceuticals L.P. PHARMACEUTICAL RESINATE COMPOSITIONS AND METHOD FOR THE PRODUCTION AND USE THEREOF

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5369822A (en) * 1976-11-26 1978-06-21 Pennwalt Corp Pharmaceutical agent
JP2016222730A (ja) * 2000-02-08 2016-12-28 ユーロ−セルティーク エス．エイ． オピオイドアゴニストおよびアンタゴニストを含む制御放出組成物
JP2009530298A (ja) * 2006-03-16 2009-08-27 トリス・フアルマ・インコーポレーテツド 薬剤−イオン交換樹脂複合体を含有する放出調節製剤
JP2010529040A (ja) * 2007-05-30 2010-08-26 ネオス・セラピューティクス・エルピー イオン性樹脂系の懸濁液における薬物放出の調節
US20140093578A1 (en) * 2010-10-20 2014-04-03 Tris Pharma, Inc. Novel clonidine formulation
JP2016516698A (ja) * 2013-03-13 2016-06-09 トリス・フアルマ・インコーポレーテツド ベンゾナテート改変放出性固体錠剤およびカプセル剤

Also Published As

Publication number Publication date
EP3694555A1 (en) 2020-08-19
KR102901919B1 (ko) 2025-12-17
AU2022201848A1 (en) 2022-04-14
IL311303B2 (en) 2026-05-01
US20200253956A1 (en) 2020-08-13
CN111629758A (zh) 2020-09-04
EP3694555A4 (en) 2021-07-07
CN119524126A (zh) 2025-02-28
CA3078844A1 (en) 2019-04-18
AU2022201848B2 (en) 2024-06-13
IL273904B1 (en) 2024-04-01
AU2024219439A1 (en) 2024-09-26
IL311303A (en) 2024-05-01
US11690840B2 (en) 2023-07-04
AU2018347991A1 (en) 2020-05-07
IL311303B1 (en) 2026-01-01
US20230285388A1 (en) 2023-09-14
US20250375438A1 (en) 2025-12-11
IL273904B2 (en) 2024-08-01
IL273904A (en) 2020-05-31
JP2023123471A (ja) 2023-09-05
KR20200097685A (ko) 2020-08-19
BR112020007061A2 (pt) 2020-10-06
WO2019074829A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
US12128042B2 (en) Tamper resistant immediate release formulations
CA2849355C (en) Tamper resistant pharmaceutical formulations
US20250352538A1 (en) Pharmaceutical resinate compositions and methods of making and using thereof
CN103415285A (zh) 包含阿片样激动剂和被隔离的拮抗剂的药物组合物
US20250375438A1 (en) Pharmaceutical resinate compositions and methods of making and using thereof
JP2024009940A (ja) 遅延放出ゲル化剤組成物を含む医薬組成物
BR112020007061B1 (pt) Composição farmacêutica de liberação controlada resistente a adulterações e abusos, e uso da mesma no tratamento da dor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211005

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230601

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230731

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250729

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20251219